Exact Mass: 465.3606602

Exact Mass Matches: 465.3606602

Found 98 metabolites which its exact mass value is equals to given mass value 465.3606602, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

LysoSM(d18:1)

{[(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl]oxy}[2-(trimethylazaniumyl)ethoxy]phosphinic acid

C23H50N2O5P+ (465.34571600000004)


D-erythro-sphingosylphosphorylcholine is an intermediate in Sphingolipid metabolism. D-erythro-sphingosylphosphorylcholine is the 5th to last step in the synthesis of Digalactosylceramidesulfate and is converted from Sphingosine via the enzyme sphingosine cholinephosphotransferase ( EC 2.7.8.10). It is then converted to Sphingomyelin via the enzyme sphingosine N-acyltransferase (EC 2.3.1.24). [HMDB] D-erythro-sphingosylphosphorylcholine is an intermediate in Sphingolipid metabolism. D-erythro-sphingosylphosphorylcholine is the 5th to last step in the synthesis of Digalactosylceramidesulfate and is converted from Sphingosine via the enzyme sphingosine cholinephosphotransferase ( EC 2.7.8.10). It is then converted to Sphingomyelin via the enzyme sphingosine N-acyltransferase (EC 2.3.1.24).

   

LysoPE(P-18:0/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-[(1Z)-octadec-1-en-1-yloxy]propoxy]phosphinic acid

C23H48NO6P (465.3219078)


LysoPE(P-18:0/0:0) is a phospho-ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin and choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

   

(8Z,11Z,13E,15S)-15-Hydroxyicosa-8,11,13-trienoylcarnitine

3-[(15-hydroxyicosa-8,11,13-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


(8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8S,9Z,11E,14Z)-8-Hydroxyicosa-9,11,14-trienoylcarnitine

3-[(8-hydroxyicosa-9,11,14-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


(8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Icosa-5,8,11-trienoylcarnitine

3-[(3-hydroxyicosa-5,8,11-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


3-Icosa-5,8,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyicosa-5,8,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Icosa-5,8,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Icosa-5,8,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Icosa-8,11,14-trienoylcarnitine

3-[(3-hydroxyicosa-8,11,14-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


3-Icosa-8,11,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyicosa-8,11,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Icosa-8,11,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Icosa-8,11,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8Z,11Z)-Henicosa-8,11-dienoylcarnitine

3-(henicosa-8,11-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C28H51NO4 (465.38178860000005)


(8Z,11Z)-Henicosa-8,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z)-henicosa-8,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z)-Henicosa-8,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z)-Henicosa-8,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(11Z,14Z)-Henicosa-11,14-dienoylcarnitine

3-(henicosa-11,14-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C28H51NO4 (465.38178860000005)


(11Z,14Z)-Henicosa-11,14-dienoylcarnitine is an acylcarnitine. More specifically, it is an (11Z,14Z)-henicosa-11,14-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z,14Z)-Henicosa-11,14-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z,14Z)-Henicosa-11,14-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(3,4-Dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine

3-{[9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine

3-{[11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(5-Heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

3-{[7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine

3-{[9-(5-hexyl-3-methylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H47NO5 (465.3454052)


9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(5-hexyl-3-methylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   
   

Phosphatidylethanolamine lyso alkenyl 18:0

Phosphatidylethanolamine lyso alkenyl 18:0

C23H48NO6P (465.3219078)


   
   
   

Olivoretin C|olovoretin C

Olivoretin C|olovoretin C

C29H43N3O2 (465.3355098)


   
   

PC(P-15:0/0:0)

3,5,9-Trioxa-4-phosphatetracos-10-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, [R-(Z)]-

C23H48NO6P (465.3219078)


   

PE(O-18:1/0:0)

1-(9Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


   

PE(P-18:0/0:0)

1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


   

LPC O-15:1

1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine

C23H48NO6P (465.3219078)


   

LysoPE O-18:1

1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


   

Methyltrioctylammonium hydrogen sulfate

Methyltrioctylammonium hydrogen sulfate

C25H55NO4S (465.38515900000004)


   

Morpholinium, 4-ethyl-4-hexadecyl-, ethyl sulfate (1:1)

Morpholinium, 4-ethyl-4-hexadecyl-, ethyl sulfate (1:1)

C24H51NO5S (465.34877560000007)


   

Olivoretin

Olivoretin

C29H43N3O2 (465.3355098)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins

   

Olivoretin C

Olivoretin C

C29H43N3O2 (465.3355098)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins

   

Phosphoric acid, mono(2-aminoethyl) mono[2-hydroxy-3-(1-octadecenyloxy)propyl] ester, (R)-

Phosphoric acid, mono(2-aminoethyl) mono[2-hydroxy-3-(1-octadecenyloxy)propyl] ester, (R)-

C23H48NO6P (465.3219078)


   

2-Amino-3-hydroxyoctadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate

2-Amino-3-hydroxyoctadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate

C23H50N2O5P+ (465.34571600000004)


   

Olivoretin B

Olivoretin B

C29H43N3O2 (465.3355098)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins

   

(6S,9S,14R)-17-butyl-14-ethenyl-6-(methoxymethyl)-10,14-dimethyl-9-propan-2-yl-2,7,10-triazatetracyclo[9.7.1.04,19.013,18]nonadeca-1(18),3,11(19),12-tetraen-8-one

(6S,9S,14R)-17-butyl-14-ethenyl-6-(methoxymethyl)-10,14-dimethyl-9-propan-2-yl-2,7,10-triazatetracyclo[9.7.1.04,19.013,18]nonadeca-1(18),3,11(19),12-tetraen-8-one

C29H43N3O2 (465.3355098)


   

9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine

9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine

C27H47NO5 (465.3454052)


   

9-(3,4-Dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine

9-(3,4-Dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine

C27H47NO5 (465.3454052)


   

7-(5-Heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

7-(5-Heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

C27H47NO5 (465.3454052)


   

11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine

11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine

C27H47NO5 (465.3454052)


   
   

3-Icosa-5,8,11-trienoylcarnitine

3-Icosa-5,8,11-trienoylcarnitine

C27H47NO5 (465.3454052)


   

3-Icosa-8,11,14-trienoylcarnitine

3-Icosa-8,11,14-trienoylcarnitine

C27H47NO5 (465.3454052)


   

(8Z,11Z)-Henicosa-8,11-dienoylcarnitine

(8Z,11Z)-Henicosa-8,11-dienoylcarnitine

C28H51NO4 (465.38178860000005)


   

(11Z,14Z)-Henicosa-11,14-dienoylcarnitine

(11Z,14Z)-Henicosa-11,14-dienoylcarnitine

C28H51NO4 (465.38178860000005)


   

(8S,9Z,11E,14Z)-8-Hydroxyicosa-9,11,14-trienoylcarnitine

(8S,9Z,11E,14Z)-8-Hydroxyicosa-9,11,14-trienoylcarnitine

C27H47NO5 (465.3454052)


   

(8Z,11Z,13E,15S)-15-Hydroxyicosa-8,11,13-trienoylcarnitine

(8Z,11Z,13E,15S)-15-Hydroxyicosa-8,11,13-trienoylcarnitine

C27H47NO5 (465.3454052)


   

(24S)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oate

(24S)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oate

C27H45O6- (465.321597)


3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oate with S configuration at C-24; major microspecies at pH 7.3.

   

Phosphatidylethanolamine lyso alkenyl 18

Phosphatidylethanolamine lyso alkenyl 18

C23H48NO6P (465.3219078)


   

3alpha,7alpha,12alpha,24-Tetrahydroxy-5beta-cholestan-26-oate

3alpha,7alpha,12alpha,24-Tetrahydroxy-5beta-cholestan-26-oate

C27H45O6- (465.321597)


The steroid acid anion formed by proton loss from the carboxy group of 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid; major micro-species at pH 7.3.

   

2-azaniumylethyl (2R)-2-hydroxy-3-[(octadec-1-en-1-yl)oxy]propyl phosphate

2-azaniumylethyl (2R)-2-hydroxy-3-[(octadec-1-en-1-yl)oxy]propyl phosphate

C23H48NO6P (465.3219078)


   

2-aminoethyl [2-hydroxy-3-[(Z)-octadec-9-enoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(Z)-octadec-9-enoxy]propyl] hydrogen phosphate

C23H48NO6P (465.3219078)


   

[2-hydroxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C23H48NO6P (465.3219078)


   

3-Hydroxy-2-(2-hydroxydodecanoylamino)undecane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxydodecanoylamino)undecane-1-sulfonic acid

C23H47NO6S (465.31239220000003)


   

3-Hydroxy-2-(2-hydroxytridecanoylamino)decane-1-sulfonic acid

3-Hydroxy-2-(2-hydroxytridecanoylamino)decane-1-sulfonic acid

C23H47NO6S (465.31239220000003)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tetradec-9-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tetradec-9-enamide

C28H51NO4 (465.38178860000005)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]tridec-8-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]tridec-8-enamide

C28H51NO4 (465.38178860000005)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]dodec-5-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]dodec-5-enamide

C28H51NO4 (465.38178860000005)


   
   
   
   
   
   
   
   
   
   
   
   
   

Octadecenyllysoplasmenylethanolamine

Octadecenyllysoplasmenylethanolamine

C23H48NO6P (465.3219078)


   
   

1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


   

1-(9Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

1-(9Z-octadecenyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


   

1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine

1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine

C23H48NO6P (465.3219078)


   

1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion

1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion

C23H48NO6P (465.3219078)


1-(alk-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl group is specified as octadec-1-enyl.

   

1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine

1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


1-(alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl group is specified as octadec-1-enyl.

   

1-[(1Z)-octadec-1-enyl]-sn-glycero-3-phosphoethanolamine

1-[(1Z)-octadec-1-enyl]-sn-glycero-3-phosphoethanolamine

C23H48NO6P (465.3219078)


A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group is specified as (1Z)-octadec-1-enyl.

   

LdMePE(16:1)

LdMePE(16:1(1))

C23H48NO6P (465.3219078)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   

NA-Dopamine 22:5(7Z,10Z,13Z,16Z,19Z)

NA-Dopamine 22:5(7Z,10Z,13Z,16Z,19Z)

C30H43NO3 (465.3242768)


   

NA-Glu 22:2(13Z,16Z)

NA-Glu 22:2(13Z,16Z)

C27H47NO5 (465.3454052)


   
   
   

LPC P-15:0 or LPC O-15:1

LPC P-15:0 or LPC O-15:1

C23H48NO6P (465.3219078)


   
   

LPE P-18:0 or LPE O-18:1

LPE P-18:0 or LPE O-18:1

C23H48NO6P (465.3219078)


   
   

(6s,9s,14r,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14r,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C29H43N3O2 (465.3355098)


   

n-{3-[n-(5-carbamimidamidopentyl)dodecanamido]propyl}-3-methylbut-2-enimidic acid

n-{3-[n-(5-carbamimidamidopentyl)dodecanamido]propyl}-3-methylbut-2-enimidic acid

C26H51N5O2 (465.4042546)


   

(6s,9s,14s,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14s,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C29H43N3O2 (465.3355098)


   

(2r)-3-[(2,12-dimethyltridecanoyl)oxy]-2-hydroxypropyl 2-(trimethylammonio)ethylphosphonate

(2r)-3-[(2,12-dimethyltridecanoyl)oxy]-2-hydroxypropyl 2-(trimethylammonio)ethylphosphonate

C23H48NO6P (465.3219078)


   

(2e,4e)-10-[(2r,3s,4r,6r,8s,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

(2e,4e)-10-[(2r,3s,4r,6r,8s,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

C27H47NO5 (465.3454052)


   

n-[(1s,3as,3bs,5ar,7s,9ar,9bs,11as)-1-[(1s)-1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

n-[(1s,3as,3bs,5ar,7s,9ar,9bs,11as)-1-[(1s)-1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

C29H43N3O2 (465.3355098)


   

(4s,6s,8s,10s,12s,13e,15e)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene

(4s,6s,8s,10s,12s,13e,15e)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene

C27H47NO5 (465.3454052)


   

n-{1-[1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl}pyridine-3-carboximidic acid

n-{1-[1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl}pyridine-3-carboximidic acid

C29H43N3O2 (465.3355098)


   

10-{4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl}-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

10-{4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl}-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

C27H47NO5 (465.3454052)


   

(6s,9s,14r,17r)-17-tert-butyl-14-ethenyl-9-isopropyl-6-(methoxymethyl)-10,14-dimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14r,17r)-17-tert-butyl-14-ethenyl-9-isopropyl-6-(methoxymethyl)-10,14-dimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C29H43N3O2 (465.3355098)


   

(2e,4e)-10-[(2r,3s,4r,6r,8r,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

(2e,4e)-10-[(2r,3s,4r,6r,8r,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid

C27H47NO5 (465.3454052)


   

(4s,6s,8s,10s,12s,13e,15e,18s)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene

(4s,6s,8s,10s,12s,13e,15e,18s)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene

C27H47NO5 (465.3454052)


   

(6s,9s,14r,17r)-14-ethenyl-9,17-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14r,17r)-14-ethenyl-9,17-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C29H43N3O2 (465.3355098)